{'fraction_non_alphanumeric': 0.05083179297597042, 'fraction_numerical': 0.012939001848428836, 'mean_word_length': 5.446428571428571, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Engineering an alginate/β-glycerophosphate/dextran injectable hydrogel-delivery for cardiac therapies after acute myocardial infarctions

Human mesenchymal stem cell therapy (hMSCs) enables the transmission of alginate (A)/dextran (D)/β- glycerophosphate (β-GP) to the human myocardials infarcts. The fabricated hMSCs-AD@β-GP exhibited pixelation rate, pore size, absorbency, and aggregation rate values of
 65.3%, 146.2%, 92.0%, and 29.1% with 1%, respectively. The hMSCs-AD@β-GP produced were physiochemically examined and were found to be highly stable, verifying the usefulness of the nanomaterials for cardiac regenerations. The in vitro studies of hMSCs- AD@β-GP hydrogels have
 indicated that the cell survival ratio improved, and the positive findings of ejection fraction, fibrosis, and vessel density with lowered infraction size indicated that the heart regenerative activity also improved significantly after myocardial infraction. The synergic effect of the hydrogel
 with hMSCs-AD@β- GP may, therefore, be suitable to treat patients with severe myocardial infarctions.